Medisafe Launches New SaMD Technology to Enhance Business Solutions

Medisafe, a digital therapeutics firm focused on medication engagement, recently introduced SaMD technology. This announcement comes months after receiving ISO 13485:2016 accreditation for medical devices and ISO 27001:2013 certification for pharmaceutical and digital health platforms. These international registrations demonstrate Medisafe’s clinical management and patient engagement leadership.

With the market for disease management software growing, Medisafe’s development shows that the company is committed to following the law, going above and beyond what is expected, and being at the forefront of SaMD development.

The achievements made by Medisafe in the past year to better serve patients, doctors, and pharma partners have earned the company a great deal of pride. Medisafe remarked that the most recent announcement of registering as a SaMD is not only a crucial step in the company’s development, but it is also essential that it anticipate and address changing customer and industry needs, both regulated and unregulated, as leaders and innovators in digital therapeutics.

Medisafe continues to focus on non-regulated business-building solutions that exceed the needs of pharma, HUBs, providers, and patients.

Through an interoperable, individualized, and patient-centric approach to digital patient connectivity, Medisafe’s end-to-end Care Connector platform enables organizations to effectively engage with patients throughout the medication journey, supporting pharma’s vision for a more digitally enhanced future. More than 10 million registrants utilize and rely on Medisafe’s platform and digital drug companion to manage their medications, validating the value it brings to patients.

Meanwhile, Medisafe will attend the 41st Annual J.P. Morgan Healthcare Conference, which will take place on January 9–12, 2023, in San Francisco, CA, USA.